GO:0015912 short-chain fatty acid transport: Transport Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0015912 short-chain fatty acid transport describes the directed movement of short-chain fatty acids (SCFAs, fewer than 6 carbons) into, out of, or within cells by transporters or pores.
• SCFA transport is central to colonic homeostasis, where absorbed butyrate, propionate, and acetate fuel colonocytes and regulate ion and water absorption.
• Key transport proteins include SLC16A1 (MCT1), SLC16A3 (MCT4), SLC5A8 (SMCT1), and SLC26A3 (DRA), which mediate pH- and sodium-dependent SCFA movement.
• Altered SCFA transport contributes to diarrheal disease, inflammatory bowel disease, and systemic inflammation, and is being explored in irritable bowel syndrome and sepsis.
• Gut-derived SCFAs such as butyrate influence distant organs, including the ocular surface and the central nervous system, highlighting the systemic reach of SCFA transport.
• CRISPR knockout, point-mutation, knock-in, and overexpression models enable causal testing of SCFA transporter genes in vitro and in vivo.
Description
Short-chain fatty acids (SCFAs) are carboxylic acids with aliphatic tails of fewer than six carbons, and their movement across cell membranes is a biologically essential process captured by the Gene Ontology term GO:0015912, short-chain fatty acid transport. This term describes the directed movement of SCFAs into, out of, or within a cell, or between cells, by means of some agent such as a transporter or pore. Because SCFAs are produced in large quantities by microbial fermentation of dietary fiber in the colon, their transport is a critical interface between the gut microbiome and host physiology. Researchers study GO:0015912 because SCFA transport determines how much butyrate, propionate, and acetate reach colonocytes and peripheral tissues, thereby influencing energy metabolism, barrier function, immune regulation, and systemic inflammation. Defects in SCFA transport are linked to diarrheal disorders, inflammatory conditions, and metabolic dysfunction, making the transporters attractive experimental targets. The term also connects to broader questions in microbiome-host signaling, including how gut-derived SCFAs affect organs such as the eye and the brain. This article integrates the QuickGO definition of GO:0015912 with verified PubMed literature to summarize the mechanism, key genes, disease relevance, and research methods used to interrogate short-chain fatty acid transport.
short-chain fatty acid transport At A Glance
| GO ID | GO:0015912 |
|---|---|
| GO term | short-chain fatty acid transport |
| Ontology | biological_process |
| Synonym | none |
| Major function | Directed movement of SCFAs (fewer than 6 carbons) into, out of, or within cells via transporters or pores |
| Substrates | Acetate, propionate, butyrate, and related short-chain fatty acids |
| Representative transporters | SLC16A1 (MCT1), SLC16A3 (MCT4), SLC5A8 (SMCT1), SLC26A3 (DRA) |
| Physiological context | Colonic absorption, colonocyte energy metabolism, ion and water balance |
| Disease relevance | Diarrhea, inflammatory bowel disease, irritable bowel syndrome, sepsis, ocular and neuroimmune conditions |
What Is GO:0015912?
GO:0015912 short-chain fatty acid transport is a biological process defined as the directed movement of short-chain fatty acids into, out of, or within a cell, or between cells, by means of some agent such as a transporter or pore; a short-chain fatty acid has an aliphatic tail containing fewer than 6 carbons. In practice, this encompasses carrier-mediated and channel-mediated fluxes of acetate, propionate, butyrate, and related SCFAs across plasma and organelle membranes.
Why Is short-chain fatty acid transport Important in Cell Biology?
Short-chain fatty acid transport is important because it governs the host availability of microbial metabolites that shape colonocyte energy supply, epithelial barrier integrity, immune tone, and systemic inflammation. Without efficient transport, SCFAs produced by the gut microbiota cannot reach their cellular targets, and impaired transport has been implicated in diarrheal disease, inflammatory conditions, and microbiome-associated disorders. Consequently, GO:0015912 sits at the crossroads of gastroenterology, immunology, and metabolism, and it is a frequent focus of both mechanistic and translational research.
• Maintains colonic homeostasis by enabling butyrate uptake and oxidation in colonocytes.
• Supports ion and water absorption, and its dysfunction contributes to diarrhea.
• Links gut microbial fermentation to host energy metabolism and barrier function.
• Modulates inflammatory responses in the intestine and at distant sites such as the ocular surface.
• Influences neuroimmune and behavioral phenotypes in mouse models of autism spectrum disorder.
• Is relevant to irritable bowel syndrome, where SCFA-producing probiotics may improve symptoms and barrier function.
• Contributes to systemic inflammation and organ dysfunction in sepsis.
• Provides druggable and genetically tractable targets for CRISPR-based functional studies.
• Helps explain how dietary fiber exerts anti-inflammatory effects through SCFA signaling.
• Offers biomarkers and intervention points for inflammatory diarrhea and mucosal health.
What Happens During short-chain fatty acid transport?
Luminal production and availability of SCFAs
In simple terms: Gut bacteria make short-chain fatty acids from fiber, and these acids must be available at the cell surface before transport can occur.
SCFAs are generated by microbial fermentation of dietary fiber in the colon, creating a luminal pool of acetate, propionate, and butyrate that is available for absorption. The size and composition of this pool depend on diet, microbiota composition, and transit time, and it determines the substrate load presented to transport proteins. In inflammatory diarrhea models, oral tributyrin, a butyrate prodrug, alters SCFA transport and mucosal health, illustrating how luminal substrate supply can be manipulated experimentally.
Apical uptake by colonocytes
In simple terms: Specialized proteins on the gut-facing side of colon cells take up short-chain fatty acids from the gut lumen.
Apical uptake of SCFAs in the colon involves transport proteins such as SLC5A8 (SMCT1) and SLC26A3 (DRA), which contribute to sodium-dependent and anion-exchange mechanisms, respectively. These transporters help move SCFAs and associated ions across the apical membrane, coupling SCFA absorption to electrolyte and water handling. The coordinated activity of apical transporters is essential for colonic homeostasis and for preventing osmotic diarrhea.
Basolateral export and systemic delivery
In simple terms: After entering colon cells, short-chain fatty acids can leave through the blood-facing side to reach the rest of the body.
Basolateral export of SCFAs is mediated in part by monocarboxylate transporters such as SLC16A1 (MCT1) and SLC16A3 (MCT4), which facilitate proton-linked movement of monocarboxylates across membranes. This export step allows SCFAs that are not oxidized locally to enter the portal circulation and reach peripheral tissues, where they influence metabolism and immune function. Gut-derived butyrate has been shown to suppress ocular surface inflammation, demonstrating that basolateral export and systemic delivery are functionally consequential beyond the colon.
Intracellular utilization and signaling
In simple terms: Once inside cells, short-chain fatty acids are used as fuel or act as signals that change cell behavior.
Butyrate is a preferred energy substrate for colonocytes and also acts as a signaling molecule that influences gene expression, barrier function, and inflammation. Intracellular SCFA availability depends on the balance between uptake, export, and metabolic consumption, so transport proteins indirectly shape signaling outcomes. In mouse models of autism spectrum disorder, microbial-mediated changes in social behavior involve SCFA-dependent mechanisms, underscoring that intracellular and systemic SCFA handling can affect neurobiology.
Integration with ion and water transport
In simple terms: Short-chain fatty acid transport is tied to the movement of salt and water in the gut.
Colonic SCFA absorption is functionally coupled to sodium and chloride transport pathways, and this coupling is central to normal stool formation. When SCFA transport is impaired, the resulting electrolyte and water imbalances can contribute to diarrheal disease. This integration explains why SCFA transport is studied not only as a metabolic process but also as a determinant of intestinal fluid homeostasis.
Key Genes Involved in GO:0015912 short-chain fatty acid transport
The following genes and proteins are central to short-chain fatty acid transport and are frequently studied in mechanistic and translational research.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SLC16A1 (MCT1) | Proton-linked monocarboxylate transporter mediating SCFA movement across membranes | Target for studying basolateral SCFA export and metabolic coupling |
| SLC16A3 (MCT4) | Monocarboxylate transporter contributing to SCFA and lactate flux | Model for transporter redundancy and substrate specificity |
| SLC5A8 (SMCT1) | Sodium-coupled monocarboxylate transporter involved in apical SCFA uptake | Key gene for colonic SCFA absorption and tumor suppressor studies |
| SLC26A3 (DRA) | Anion exchanger linked to chloride and SCFA-related transport in the colon | Relevant to diarrheal disease and electrolyte balance |
| SLC26A2 | Anion transporter family member with roles in sulfate and related transport | Comparative model for anion transport specificity |
| SLC16A7 (MCT2) | Monocarboxylate transporter with tissue-specific expression | Used to dissect transporter isoform functions |
| SLC16A8 (MCT3) | Monocarboxylate transporter expressed in specific epithelia | Model for tissue-restricted SCFA transport |
| SLC16A4 (MCT5) | Monocarboxylate transporter family member | Candidate for orphan monocarboxylate transport |
| SLC16A5 (MCT6) | Monocarboxylate transporter family member | Explored in transporter profiling studies |
| SLC16A6 (MCT7) | Monocarboxylate transporter family member | Potential contributor to SCFA handling |
| SLC16A10 (MCT10) | Aromatic amino acid transporter with broader substrate range | Used to test substrate overlap with SCFAs |
| SLC16A11 | Monocarboxylate transporter family member | Studied in metabolic and transport screens |
| SLC16A12 | Monocarboxylate transporter family member | Candidate for epithelial transport functions |
| SLC16A13 | Monocarboxylate transporter family member | Included in transporter expression panels |
| SLC16A14 | Monocarboxylate transporter family member | Potential SCFA transport contributor |
| SLC5A12 | Sodium-coupled monocarboxylate transporter family member | Relevant to sodium-dependent SCFA uptake |
| SLC5A8 paralogs | Related sodium-coupled transporters | Used to define transport mechanism families |
| SLC26A3 paralogs | Related anion exchangers | Comparative models for colonic anion transport |
How Is short-chain fatty acid transport Regulated?
Short-chain fatty acid transport is regulated at multiple levels, including transporter expression, substrate availability, and the luminal environment. The abundance of transporters such as SLC16A1 and SLC5A8 can change in response to dietary fiber, microbial metabolites, and inflammatory signals, thereby adjusting SCFA flux to physiological demand. In inflammatory diarrhea models, oral tributyrin treatment affects SCFA transport, mucosal health, and the microbiome, indicating that substrate supply and transport capacity are co-regulated. Because SCFA transport is coupled to ion and water movement, regulatory inputs that alter electrolyte transport also indirectly influence SCFA handling. These layers of regulation make GO:0015912 a dynamic process rather than a fixed membrane property.
short-chain fatty acid transport and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SLC16A1 (MCT1) | SCFA export and metabolic coupling in inflammation | Knockout and overexpression in colonocyte cell lines |
| SLC5A8 (SMCT1) | Colonic SCFA uptake and tumor suppressor biology | Point-mutation and knockout models in intestinal epithelium |
| SLC26A3 (DRA) | Diarrheal disease and electrolyte imbalance | Knockout mouse models of inflammatory diarrhea |
| SLC16A3 (MCT4) | Systemic SCFA delivery and inflammation | Tagged knock-in for localization studies |
| SLC5A12 | Sodium-coupled SCFA transport | Overexpression in epithelial cells for transport assays |
Short-chain fatty acid transport in diarrheal disease
Colonic SCFA transport is mechanistically linked to ion and water absorption, and its impairment contributes to diarrheal disease. When SCFA absorption is compromised, the resulting osmotic and electrolyte imbalances can worsen fluid loss. Experimental models of inflammatory diarrhea show that modulating SCFA supply with tributyrin affects transport, mucosal health, and the microbiome, supporting a causal role for SCFA handling in disease severity.
Irritable bowel syndrome and barrier function
In irritable bowel syndrome, interventions that increase SCFA-producing probiotic metabolites have been tested for symptom relief and intestinal barrier improvement in randomized controlled trials. These findings suggest that SCFA availability and transport influence barrier function and symptom burden. Because SCFA transport determines how much metabolite reaches the epithelium, it is a plausible mediator of these clinical effects.
Systemic inflammation and sepsis
The gut microbiome and SCFA metabolites are increasingly recognized as contributors to sepsis pathophysiology. SCFA transport determines the systemic exposure to microbial metabolites that can modulate immune responses during critical illness. This connection positions SCFA transporters as potential nodes for understanding and potentially intervening in sepsis-associated inflammation.
Gut-derived SCFAs and distant organ effects
Gut-derived butyrate can suppress ocular surface inflammation, demonstrating that SCFA transport and systemic delivery affect organs beyond the intestine. In mouse models of autism spectrum disorder, microbial-mediated changes in social behavior involve SCFA-dependent mechanisms, linking SCFA handling to neurobiology. These examples illustrate that GO:0015912 has implications for immune and neurological conditions through gut-organ axes.
From short-chain fatty acid transport-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is a transporter required for SCFA uptake? | CRISPR knockout in colonocyte cell lines |
| Does a specific residue control substrate specificity? | CRISPR point mutation at the predicted substrate-binding site |
| Can a disease-associated variant alter transport? | CRISPR knock-in of the variant allele |
| Where is the transporter expressed in tissue? | Tagged knock-in with a fluorescent or epitope tag |
| Does increased transporter abundance enhance SCFA flux? | CRISPR overexpression or cDNA overexpression |
| Which transporters compensate when one is lost? | CRISPR library screening and transcriptomic profiling |
How to Study the short-chain fatty acid transport Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Radiolabeled SCFA uptake assay | Transport rate across membranes | Quantifying transporter activity in cell lines |
| pH and ion substitution assays | Proton and sodium dependence of transport | Defining transport mechanism |
| RNA sequencing | Transporter gene expression profiles | Identifying regulated transporters in disease models |
| 16S rRNA sequencing | Microbial community composition | Linking SCFA producers to host transport |
| Metabolomics | Luminal and systemic SCFA concentrations | Measuring substrate availability |
| CRISPR knockout | Loss-of-function effects on transport | Testing transporter necessity |
| CRISPR knock-in | Variant or tag effects on transport | Modeling disease variants and localization |
| Immunofluorescence imaging | Transporter localization in tissue | Validating apical versus basolateral distribution |
Transport assays and flux measurements
Direct measurement of SCFA transport is typically performed using radiolabeled or fluorescent SCFA analogs in cultured epithelial cells, allowing quantification of uptake and efflux rates. These assays can be combined with ion substitution and pH clamping to define sodium dependence and proton coupling. In vivo, luminal perfusion and fecal metabolite measurements provide integrated readouts of transport capacity.
Expression profiling and transcriptomics
RNA sequencing and targeted expression panels are used to quantify SLC16, SLC5A8, and SLC26 family transporters across tissues and conditions. Such profiling helps identify which transporters are co-expressed with SCFA-metabolizing enzymes and which change in disease models. Transcriptomic data from inflammatory diarrhea models can reveal coordinated regulation of transport and mucosal health genes.
Microbiome and metabolite analysis
Because SCFA transport depends on microbial production, 16S rRNA sequencing and metabolomics are often combined with transport studies. These approaches quantify the luminal SCFA pool and link it to host transporter expression and function. In clinical studies, probiotic interventions that alter SCFA-producing metabolites can be monitored alongside symptom and barrier endpoints.
Genetic and pharmacological perturbation
CRISPR-based knockout, point mutation, knock-in, and overexpression models allow causal testing of individual transporters in SCFA handling. Pharmacological inhibitors of monocarboxylate transporters can complement genetic approaches to dissect acute versus chronic effects. Together, these methods connect molecular transport activity to physiological and disease phenotypes.
How CRISPR Can Be Used to Study GO:0015912 short-chain fatty acid transport
Knockout
CRISPR knockout of SCFA transporter genes such as SLC16A1, SLC5A8, or SLC26A3 in colonocyte cell lines provides a clean loss-of-function context to test whether a given transporter is required for SCFA uptake or export. Knockout models can be combined with transport assays and transcriptomics to reveal compensatory changes in other transporters. In vivo knockout of SLC26A3 is relevant to diarrheal disease models and electrolyte imbalance.
Point Mutation
CRISPR point mutation enables precise editing of residues predicted to mediate substrate binding, proton coupling, or sodium coordination in SCFA transporters. Such models are valuable for dissecting structure-function relationships without confounding effects from complete gene loss. They can also be used to test whether specific residues are required for transport-coupled ion movement.
Knock-in
CRISPR knock-in can introduce disease-associated variants or epitope tags into endogenous SCFA transporter loci. Tagged knock-in lines allow visualization of transporter localization and trafficking in physiologically relevant contexts. Variant knock-in models help determine whether a genetic change alters SCFA transport function or regulation.
Overexpression
CRISPR overexpression or cDNA-based overexpression of SCFA transporters increases transport capacity and can reveal rate-limiting steps in SCFA handling. Overexpression models are useful for testing whether enhanced SCFA flux alters downstream signaling, barrier function, or inflammatory responses. They also support drug screening efforts aimed at modulating SCFA transport.
How EDITGENE Supports short-chain fatty acid transport Research
Researchers studying short-chain fatty acid transport-related genes often need to determine whether a candidate gene is causally involved in SCFA uptake, export, or downstream physiology. EDITGENE provides CRISPR-based cell models and screening services that allow precise, reproducible interrogation of GO:0015912-associated genes in relevant cellular contexts.
Contact EDITGENE today to design your custom CRISPR model for short-chain fatty acid transport research.
Frequently Asked Questions About short-chain fatty acid transport
What is GO:0015912 short-chain fatty acid transport?
GO:0015912 is a Gene Ontology biological process term describing the directed movement of short-chain fatty acids (fewer than 6 carbons) into, out of, or within a cell, or between cells, by means of a transporter or pore.
What genes are involved in short-chain fatty acid transport?
Key genes include SLC16A1 (MCT1), SLC16A3 (MCT4), SLC5A8 (SMCT1), and SLC26A3 (DRA), which mediate monocarboxylate and anion transport across cell membranes.
Why is short-chain fatty acid transport important for colon health?
It enables colonocytes to absorb and metabolize butyrate and other SCFAs, supports ion and water absorption, and helps maintain the intestinal barrier.
How is short-chain fatty acid transport studied experimentally?
Researchers use radiolabeled uptake assays, RNA sequencing, metabolomics, microbiome profiling, and CRISPR-based genetic models to measure and perturb SCFA transport.
What diseases are linked to defective short-chain fatty acid transport?
Impaired SCFA transport has been linked to diarrheal disease, inflammatory bowel conditions, irritable bowel syndrome, and systemic inflammation such as sepsis.
Can CRISPR be used to study SCFA transporters?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models allow causal testing of individual SCFA transporter genes in cell and animal systems.
Which transporters mediate butyrate uptake in the colon?
Butyrate uptake involves transporters such as SLC5A8 (SMCT1) and SLC26A3 (DRA) at the apical membrane, with SLC16A1 (MCT1) contributing to basolateral export.
How do gut-derived SCFAs affect organs outside the gut?
After transport into the circulation, SCFAs such as butyrate can modulate inflammation at distant sites, including the ocular surface, and influence neuroimmune behavior in mouse models.
What is the role of SCFA transport in irritable bowel syndrome?
SCFA-producing probiotic metabolites have been tested in randomized trials for symptom relief and barrier improvement in IBS, suggesting that SCFA availability and transport influence disease activity.
How can EDITGENE help with short-chain fatty acid transport research?
EDITGENE provides CRISPR knockout, point-mutation, knock-in, overexpression, library screening, and bioinformatics services to study SCFA transporter genes and their functions.
Conclusion
GO:0015912 short-chain fatty acid transport is a biologically central process that connects gut microbial metabolism to host physiology through the directed movement of acetate, propionate, and butyrate across cell membranes. Its molecular machinery includes well-characterized transporters such as SLC16A1, SLC5A8, and SLC26A3, whose functions are relevant to diarrheal disease, inflammatory conditions, irritable bowel syndrome, and systemic inflammation. Because SCFA transport influences colonocyte energy metabolism, barrier function, and distant organ biology, it remains an active area for mechanistic and translational research. CRISPR-based models and multi-omics approaches now make it feasible to causally test SCFA transporter genes and to identify new regulators of this essential transport process.
References
- 1. Li E et al.. 2025. Effects of short-chain fatty acid-producing probiotic metabolites on symptom relief and intestinal barrier function in patients with irritable bowel syndrome: a double-blind, randomized controlled trial.. Front Cell Infect Microbiol 15:1616066 PMID: 40575487
- 2. Sivaprakasam S et al.. 2017. Short-Chain Fatty Acid Transporters: Role in Colonic Homeostasis.. Compr Physiol 8(1):299-314 PMID: 29357130
- 3. Sgritta M et al.. 2019. Mechanisms Underlying Microbial-Mediated Changes in Social Behavior in Mouse Models of Autism Spectrum Disorder.. Neuron 101(2):246-259.e6 PMID: 30522820
- 4. Binder HJ. 2010. Role of colonic short-chain fatty acid transport in diarrhea.. Annu Rev Physiol 72:297-313 PMID: 20148677
- 5. Adame MD et al.. 2026. The Gut Microbiome and Short-Chain Fatty Acid Metabolites in Sepsis.. Clin Chest Med 47(1):119-128 PMID: 41651593
- 6. Schaefer L et al.. 2022. Gut-derived butyrate suppresses ocular surface inflammation.. Sci Rep 12(1):4512 PMID: 35296712
- 7. Qu L et al.. 2026. Gut microbiota: A key player for soluble dietary fiber in regulating inflammatory disease.. J Adv Res 84:287-303 PMID: 40972715
- 8. Ye Z et al.. 2025. Oral tributyrin treatment affects short-chain fatty acid transport, mucosal health, and microbiome in a mouse model of inflammatory diarrhea.. J Nutr Biochem 138:109847 PMID: 39870330
